Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Annals of Nuclear Medicine
Published in: Annals of Nuclear Medicine 9/2023

18-06-2023 | Prostate Cancer | Original Article

Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy

Authors: Yunus Güzel, Halil Kömek, Canan Can, İhsan Kaplan, Nadiye Akdeniz, Ferat Kepenek, Cihan Gündoğan

Published in: Annals of Nuclear Medicine | Issue 9/2023

Login to get access

Abstract

Objective

The aim of this study was to determine the prognostic role of volumetric parameters and Pro-PET scores obtained from 68 Ga-prostate-specific membrane antigen (PSMA) PET/CT and 18F-FDG PET/CT in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving taxane therapy.

Materials and methods

The study included 71 patients who underwent simultaneous PSMA and 18F-FDG PET/CT imaging between January 2019 and January 2022, had a Pro-PET score of 3–5 and had received taxane therapy after imaging. 18F-FDG tumor volume (TV-F) and PSMA tumor volume (TV-P) values of the lesions and total lesion glycolysis (TL-G) and total lesion PSMA (TL-P) values of the lesions were calculated on both imaging studies and the effects of these parameters on overall survival (OS) were investigated.

Results

The median age of the patients included herein was 71 years (56–89) and the median prostate-specific antigen (PSA) level was 16.4 (0.01–1852 ng/dL). According to the Kaplan–Meier survival analysis, TTV-P ≥ 78.5, TTL-P ≥ 278.8, TTV-F ≥ 94.98, TTL-G ≥ 458.3, TTV-P + F ≥ 195.45, TTL-G + P ≥ 855.78, lymph node (L)TV-FDG ≥ 3.4, LFDG-SUVmax ≥ 3.2, LFDG-SUVmean ≥ 2.25, LFDG-SUVpeak ≥ 2.55, and bone (B)TV-F ≥ 51.15 values were found to be prognostic factors in predicting short OS. Multivariate Cox regression analysis showed that a Vscore ≥ 3 (95% confidence interval [CI]: 7.069–98.251, p < 0.001) and TTL-G + P ≥ 855.78 (95% CI: 4.878–1037.860, p = 0.006) were found to be independent prognostic factors in predicting short OS.

Conclusion

Volumetric parameters and Pro-PET scores obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT imaging have been shown to have an impact on OS in patients with mCRPC receiving taxane therapy.
Literature
1.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. PubMedCrossRef
2.
Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6:76–85 ( Erratum in: Nat Clin Pract Urol. 2009;6:173). PubMedPubMedCentralCrossRef
3.
Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015;15:701–11. PubMedPubMedCentralCrossRef
4.
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1:18–28. PubMedCrossRef
5.
Bagguley D, Ong S, Buteau JP, Koschel S, Dhiantravan N, Hofman MS, et al. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer. Future Oncol. 2021;17:2225–41. PubMedCrossRef
6.
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–78. PubMedPubMedCentralCrossRef
7.
8.
Wang J, Xu W, Wang B, Lin G, Wei Y, Abudurexiti M, et al. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett. 2020;485:45–55. PubMedCrossRef
9.
Fox JJ, Gavane SC, Blanc-Autran E, Nehmeh S, Gönen M, Beattie B, et al. Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer. JAMA Oncol. 2018;4:217–24. PubMedCrossRef
10.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. PubMedCrossRef
11.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, et al. TROPIC investigators. prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. PubMedCrossRef
12.
Fitzpatrick JM, de Wit R. Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer. Eur Urol. 2014;65:1198–204. PubMedCrossRef
13.
Puente J, Grande E, Medina A, Maroto P, Lainez N, Arranz JA. Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. Ther Adv Med Oncol. 2017;9:307–18. PubMedPubMedCentralCrossRef
14.
Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J Nucl Med. 2018;59:469–78. PubMedCrossRef
15.
Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014–24. PubMedCrossRef
16.
Adnan A, Basu S. Concept proposal for a six-tier integrated dual tracer PET-CT (68Ga-PSMA and FDG) image scoring system (“Pro-PET” score) and examining its potential implications in metastatic castration-resistant prostate carcinoma theranostics and prognosis. Nucl Med Commun. 2021;42:566–74. PubMedCrossRef
17.
Montironi R, Cimadamore A, Lopez-Beltran A, Scarpelli M, Aurilio G, Santoni M, et al. Morphologic, molecular and clinical features of aggressive variant prostate cancer. Cells. 2020;9:1073. PubMedPubMedCentralCrossRef
18.
Manucha V, Henegan J. Clinicopathologic diagnostic approach to aggressive variant prostate cancer. Arch Pathol Lab Med. 2020;144:18–23. PubMedCrossRef
19.
Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19:3621–30. PubMedPubMedCentralCrossRef
20.
21.
Schmuck S, von Klot CA, Henkenberens C, Sohns JM, Christiansen H, Wester HJ, et al. Initial experience with volumetric 68Ga-PSMA I&T PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with prostate cancer. J Nucl Med. 2017;58:1962–8. PubMedCrossRef
22.
Grubmüller B, Rasul S, Baltzer P, Fajkovic H, D’Andrea D, Berndl F, et al. Response assessment using [ 68 Ga]Ga-PSMA ligand PET in patients undergoing systemic therapy for metastatic castration-resistant prostate cancer. Prostate. 2020;80:74–82. PubMedCrossRef
23.
Oruç Z, Güzel Y, Ebinç S, Kömek H, Küçüköner M, Kaplan MA, et al. Efficacy of 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting response to second-generation androgen receptor axis-targeted therapy, and the prognosis in metastatic hormone-refractory prostate cancer patients. Nucl Med Commun. 2021;42:1336–46. PubMedCrossRef
24.
Can C, Gündoğan C, Yildirim OA, Poyraz K, Güzel Y, Kömek H. Role of 68Ga-PSMA PET/CT parameters in treatment evaluation and survival prediction in prostate cancer patients compared with biochemical response assessment. Hell J Nucl Med. 2021;24:25–35. PubMed
25.
Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, et al. Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. Ann Nucl Med. 2022;36:964–75. PubMedCrossRef
26.
Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [ 177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200–10. PubMedCrossRef
27.
28.
29.
Gallamini A, Zwarthoed C, Borra A. Positron emission tomography (PET) in oncology. Cancers (Basel). 2014;6:1821–89. PubMedCrossRef
30.
Jadvar H. Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. 2013;40:5–10. PubMedCentralCrossRef
31.
Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112:E4111–9. PubMedPubMedCentralCrossRef
32.
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11:1672–82. PubMedCrossRef
33.
Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? Int J Cancer. 2018;142:2414–24. PubMedCrossRef
34.
Bauckneht M, Bertagna F, Donegani MI, Durmo R, Miceli A, De Biasi V, et al. The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients. Prostate Cancer Prostatic Dis. 2021;24:1198–207. PubMedPubMedCentralCrossRef
35.
Wibmer AG, Morris MJ, Gonen M, Zheng J, Hricak H, Larson S, et al. Quantification of metastatic prostate cancer whole-body tumor Burden with 18F-FDG PET parameters and associations with overall survival after first-line abiraterone or enzalutamide: a single-center retrospective cohort study. J Nucl Med. 2021;62:1050–6. PubMedPubMedCentralCrossRef
36.
Ferdinandus J, Violet J, Sandhu S, Hicks RJ, Ravi Kumar AS, Iravani A, et al. Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. Eur J Nucl Med Mol Imaging. 2020;47:2322–7. PubMedCrossRef
37.
Whitney CA, Howard LE, Posadas EM, Amling CL, Aronson WJ, Cooperberg MR, et al. In men with castration-resistant prostate cancer, visceral metastases predict shorter overall survival: what predicts visceral metastases? Results from the SEARCH database. Eur Urol Focus. 2017;3:480–6. PubMedCrossRef
38.
Guijarro A, Hernández V, de la Morena JM, Jiménez-Valladolid I, Pérez-Fernández E, de la Peña E, Llorente C. Influence of the location and number of metastases in the survival of metastatic prostatic cancer patients. Actas Urol Esp. 2017;41:226–33. PubMedCrossRef
39.
Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, et al. Location of metastases in contemporary prostate cancer patients affects cancer-specific mortality. Clin Genitourin Cancer. 2018;16:376-84.e1. PubMedCrossRef
40.
Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, et al. Impact of the site of metastases on survival in patients with metastatic prostate cancer. Eur Urol. 2015;68:325–34. PubMedCrossRef
41.
Xu N, Wu YP, Ke ZB, Liang YC, Tao X, Chen SH, et al. Risk factors of developing visceral metastases at diagnosis in prostate cancer patients. Transl Cancer Res. 2019;8:928–38. PubMedPubMedCentralCrossRef
42.
43.
Wang B, Liu C, Wei Y, Meng J, Zhang Y, Gan H, et al. A Prospective trial of 68Ga-PSMA and 18F-FDG PET/CT in nonmetastatic prostate cancer patients with an early PSA progression during castration. Clin Cancer Res. 2020;26(17):4551–8. PubMedCrossRef
44.
Metadata
Title
Role of volumetric parameters obtained from 68 Ga-PSMA PET/CT and 18F-FDG PET/CT in predicting overall survival in patients with mCRPC receiving taxane therapy
Authors
Yunus Güzel
Halil Kömek
Canan Can
İhsan Kaplan
Nadiye Akdeniz
Ferat Kepenek
Cihan Gündoğan
Publication date
18-06-2023
Publisher
Springer Nature Singapore
Published in
Annals of Nuclear Medicine / Issue 9/2023
Print ISSN: 0914-7187
Electronic ISSN: 1864-6433
DOI
https://doi.org/10.1007/s12149-023-01854-9

Other articles of this Issue 9/2023

Annals of Nuclear Medicine 9/2023 Go to the issue

Original Article

Toward standardization of tau PET imaging corresponding to various tau PET tracers: a multicenter phantom study

Original Article

Quantitative analysis of lung function and airway remodeling using ventilation/perfusion single photon emission tomography/computed tomography and HRCT in patients with chronic obstructive pulmonary disease and asthma

Original Article

Performance of dedicated breast PET in breast cancer screening: comparison with digital mammography plus digital breast tomosynthesis and ultrasound

Original Article

Assessment of anti-GAD65-associated cerebellar ataxia with 18F-FDG cerebellar uptake: ROC analysis